Research information only, not medical advice. Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 23, 2026 (evaluated indication: Wound healing and inflammatory conditions). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
KPV at a glance
As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.
All seven peptides on the agenda are covered in the July 2026 FDA peptide meeting.
Evidence profile
92 studies- Human RCT 1 · 1%
- Human trial 6 · 7%
- Review 12 · 13%
- Animal 18 · 20%
- In-vitro 36 · 39%
- Unknown 19 · 21%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-22 US-FDA
Removed from the FDA 503A 'do not compound' Category 2 (nominations withdrawn) — still not eligible for compounding. source
- 2026-07-23 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee vote (evaluated indication: Wound healing and inflammatory conditions); docket FDA-2025-N-6895. source
Indexed research
Sorted by evidence level, strongest first.
- Human RCT 2025Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization
- Human trial 2024Non-contrast-enhanced magnetic resonance urography for measuring split kidney function in pediatric patients with hydronephrosis: comparison with renal scintigraphy
This retrospective study of 75 pediatric patients found that non-contrast-enhanced magnetic resonance urography can estimate split kidney function as an alternative to renal scintigraphy.
- Human trial 2022Gadoxetic Acid Uptake Rate as a Measure of Global and Regional Liver Function as Compared With Indocyanine Green Retention, Albumin-Bilirubin Score, and Portal Venous Perfusion
This study validates gadoxetic acid uptake rate as a measure of global and regional liver function by comparing it with indocyanine green retention and albumin-bilirubin score in patients with hepatocellular carcinoma.
- Human trial 2019Identification of bla(VIM-1) Gene in ST307 and ST661 Klebsiella pneumoniae Clones in Italy: Old Acquaintances for New Combinations
This study reports the genomic characterization of two VIM-1-producing Klebsiella pneumoniae isolates from patients in Italy, highlighting the emergence of new clones.
- Human trial 2024Early treatment of skeletal class III malocclusion with facemask therapy in Vietnam
This interventional trial in 31 Vietnamese children found that facemask therapy improved skeletal class III malocclusion, with better outcomes in the younger age group (7-9 years).
- Human trial 2018Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study
This Phase I-II study quantified intact CXCL12 and its truncation products in plasma from MDS and AML patients treated with rigosertib, finding that responders showed increased intact CXCL12 levels.
- Human trial 2012Abstract 2675: CXCL12 (SDF-1) and its truncation products in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) receiving ON 01910.Na (Rigosertib) in phase I trials
This phase I study in MDS/AML patients found that lower intact CXCL12 and higher truncation product levels may serve as response markers to rigosertib treatment.
- Review 2026A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
This critical review examines the limited clinical evidence and potential risks of peptide and peptide-analog drugs used for performance enhancement in sport and bodybuilding.
- Review 2025Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
- Review 2025Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
+ 82 more studies indexed for KPV.
Frequently asked questions
- Is KPV approved for human use?
- Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 23, 2026 (evaluated indication: Wound healing and inflammatory conditions). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
- What does the research on KPV show?
- As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.